Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03)

作者：Tanaka Shiro^*; Miyazaki Teruhiko; Uemura Yukari; Kuroda Tatsuhiko; Miyakawa Nobuaki; Nakamura Toshitaka; Fukunaga Masao; Ohashi Yasuo; Ohta Hiroaki; Mori Satoshi; Hagino Hiroshi; Hosoi Takayuki; Sugimoto Toshitsugu; Itoi Eiji; Orimo Hajime; Shiraki Masataka

来源：Journal of Bone and Mineral Metabolism, 2014, 32(3): 298-304.

DOI：10.1007/s00774-013-0491-4

• Bisphosphonate
• Osteoporosis
• Quality of life
• Undercarboxylated osteocalcin
• 25-Hydroxyvitamin D

Concurrent treatments with bisphosphonates and vitamin K are promising given that bisphosphonates possibly interfere with vitamin K activation. This is a prospective, multi-center, open-labeled, randomized trial of the efficacy of concurrent treatment with vitamin K-2 and risedronate compared with risedronate alone and to explore subsets of patients for which concurrent treatment is particularly efficacious (trial identification number UMIN000000991). Inclusion criteria are women who meet the criteria for pharmacological therapy for osteoporosis, aged a parts per thousand yen65 years, have any of pre-specified risk factors, can walk unassisted, and are able to answer questionnaires. Exclusion criteria are prior warfarin use, secondary osteoporosis or non-osteoporotic metabolic bone diseases, contraindication for vitamin K-2 and risedronate, hyper- or hypoparathyroidism, mental disorders, prevalent vertebral fracture at a parts per thousand yen6 sites, severe degenerative spinal deformation between T4 and L4, serious heart, liver, or kidney disease, or bisphosphonate use within the previous 6 months. Patients were recruited from 123 institutes between January 2008 and February 2010, and allocated to vitamin K-2 (45 mg/day) and risedronate (2.5 mg/day or 17.5 mg/week) or risedronate alone (2.5 mg/day or 17.5 mg/week) groups. Primary endpoint is a vertebral or non-vertebral fracture. Secondary endpoints are bone mineral density, height, undercarboxylated osteocalcin, JOQOL, EQ-5D and safety. A sample size of 910 subjects per group and 2-year follow-up will provide 80 % power to detect 35 % risk reduction for fracture, with a two-sided significance level of 5 %. Subgroup analysis stratified to adjustment factors for random allocation, body mass index, 25-hydroxyvitamin D, estimated glomerular filtration rate, grade of vertebral fracture, JOQOL, EQ-5D, and co-morbidity is pre-specified.

• 出版日期2014-5